On December 8, 2025, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the ABBV-711, developed by AbbVie — to the “first patient in the World ” as part of a global, multicenter First-in-Human Phase 1 Clinical Trial (ClinicalTrials.gov ID: NCT07241039).  The administration took place in Kansai Medical University Hospital.                                                                                    Study Details | NCT07241039 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors | ClinicalTrials.gov